Harrington, K
4087  results:
Search for persons X
?
1

Zanzalintinib Plus Pembrolizumab Versus Pembrolizumab Alone..:

Saba, N.F. ; Harrington, K. ; Licitra, L....
International Journal of Radiation Oncology*Biology*Physics.  118 (2024)  5 - p. e40-e41 , 2024
 
?
 
?
3

Lenvatinib ± Pembrolizumab Versus Chemotherapy for Recurren..:

Harrington, K. ; Kim, H.R. ; Salas, S....
International Journal of Radiation Oncology*Biology*Physics.  118 (2024)  5 - p. e42 , 2024
 
?
5

Pembrolizumab with or Without Lenvatinib As First-line Ther..:

Licitra, L. ; Tahara, M. ; Harrington, K....
International Journal of Radiation Oncology*Biology*Physics.  118 (2024)  5 - p. e2-e3 , 2024
 
?
6

PO-2279 Preliminary analysis of subcutaneous tissue fibrosi..:

Simoes, R. ; Gulliford, S. ; Seddon, B....
Radiotherapy and Oncology.  182 (2023)  - p. S2049-S2050 , 2023
 
?
 
?
8

MO-0149 Development of novel outlining normal tissue struct..:

Simoes, R. ; Shah, P. ; Augustin, Y....
Radiotherapy and Oncology.  182 (2023)  - p. S111-S112 , 2023
 
?
9

106P Treatment sequencing in PD-L1–positive recurrent/metas..:

Greil, R. ; Burtness, B. ; Laban, S....
Immuno-Oncology and Technology.  20 (2023)  - p. 100578 , 2023
 
?
 
?
13

MO-0947 Lessons learned from RT toxicity outcomes from UK V..:

Simoes, R. ; Dehbi, H. ; Gulliford, S....
Radiotherapy and Oncology.  182 (2023)  - p. S795-S796 , 2023
 
?
 
?
 
1-15